[1] [1] BHATT D L, LOPES R D, HARRINGTON R A. Diagnosis and treatment of acute coronary syndromes: a review[J]. JAMA, 2022, 327(7): 662-675.

[3] [3] ISEZUO S, SANI M U, TALLE A, et al. Registry for acute coronary events in Nigeria (RACE-Nigeria): clinical characterization, management, and outcome[J]. J Am Heart Assoc, 2022, 11(1): e020244.

[5] [5] LI M N, WANG H J, ZHANG N R, et al. MTHFR C677T gene polymorphism and the severity of coronary lesions in acute coronary syndrome[J]. Medicine (Baltimore), 2017, 96(49): e9044.

[10] [10] CIMMINO G, GALLINORO E, DI SERAFINO L, et al. Uric acid plasma levels are associated with C-reactive protein concentrations and the extent of coronary artery lesions in patients with acute coronary syndromes[J]. Intern Emerg Med, 2023, 18(6): 1751-1757.

[12] [12] REARDON M F, NESTEL P J, CRAIG I H, et al. Lipoprotein predictors of the severity of coronary artery disease in men and women[J]. Circulation, 1985, 71(5): 881-888.

[14] [14] MOHILE S, BLAUM C S, ABADIR P M, et al. AGS and NIA bench-to bedside conference summary: cancer and cardiovascular disease[J]. J Am Geriatr Soc, 2022, 70(10): 2764-2774.

[15] [15] YU T T, LUO D, LUO C C, et al. Prognostic and therapeutic value of serum lipids and a new IPI score system based on apolipoprotein A-I in diffuse large B-cell lymphoma[J]. Am J Cancer Res, 2023, 13(2): 475-484.

[17] [17] ZHENG W C, CHAN W, DART A, et al. Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease[J]. Eur Heart J Cardiovasc Pharmacother, 2024, 10(1): 53-67.

[18] [18] LIBBY P, BURING J E, BADIMON L, et al. Atherosclerosis[J]. Nat Rev Dis Primers, 2019, 5(1): 56.

[19] [19] GENCER B, MARSTON N A, IM K, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials[J]. Lancet, 2020, 396(10263): 1637-1643.

[21] [21] KHAN A W, JANDELEIT-DAHM K A M. Atherosclerosis in diabetes mellitus: novel mechanisms and mechanism-based therapeutic approaches[J]. Nat Rev Cardiol, 2025.

[22] [22] WANG X, YU D H, WANG J R, et al. Analysis of coronary artery lesion degree and related risk factors in patients with coronary heart disease based on computer-aided diagnosis of coronary angiography[J]. Comput Math Methods Med, 2021, 2021: 2370496.

[24] [24] GRECO A, FINOCCHIARO S, SPAGNOLO M, et al. Lipoprotein(a) as a pharmacological target: premises, promises, and prospects[J]. Circulation, 2025, 151(6): 400-415.

[25] [25] SINGH S S, VAN DER TOORN J E, SIJBRANDS E J G, et al. Lipoprotein(a) is associated with a larger systemic burden of arterial calcification[J]. Eur Heart J Cardiovasc Imaging, 2023, 24(8): 1102-1109.

[27] [27] VIEGAS C S B, SANTOS L, MACEDO A L, et al. Chronic kidney disease circulating calciprotein particles and extracellular vesicles promote vascular calcification: a role for GRP (gla-rich protein)[J]. Arterioscler Thromb Vasc Biol, 2018, 38(3): 575-587.

[28] [28] THEODORAKOPOULOU M P, DIPLA K, ZAFEIRIDIS A, et al. ndothelial and microvascular function in CKD: evaluation methods and associations with outcomes[J]. Eur J Clin Invest, 2021, 51(8): e13557.

[29] [29] SPEER T, DIMMELER S, SCHUNK S J, et al. Targeting innate immunity-driven inflammation in CKD and cardiovascular disease[J]. Nat Rev Nephrol, 2022, 18(12): 762-778.

[30] [30] KOH E S, KIM M, KIM M K, et al. Intra-individual variability in high density lipoprotein cholesterol and risk of end-stage renal disease: a nationwide population-based study[J]. Atherosclerosis, 2019, 286: 135-141.